“Patent losses could sink Allergan”.1 “Drug prices to plummet in wave of expiring patents”.2 “Price decay after loss of brand exclusivity”.3 These are just three headlines that come up when you Google “drug patent expiry”.4 It’s no wonder “loss of exclusivity (LOE)” or “the patent… Read More »Three strategies for managing loss of exclusivity successfully
Prescient hires three new senior members to expand its expertise and keep pace with the company’s growth LONDON, November 3, 2020 – Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members: Gordon Gochenauer, Dr. Priya Kar and… Read More »Prescient Announces Recent Appointments to its Senior Team
Shots: Formycon & Bioeq reported the BLA resubmission strategy for FYB201 (biosimilar referencing Lucentis) has been adjusted With the revised submission strategy, the companies expect a simplification of the approval procedure. The modified submission dossier is anticipated to be filed with the US FDA in… Read More »Formycon Reports BLA Resubmission Strategy for FYB201 (biosimilar, ranibizumab)
A recently released 50-page plan details the federal agency’s health IT-related objectives over the next five years and outlines the strategies it plans to use to achieve its goals.
The European data strategy aims to construct common data spaces for all, create a single EU market for data, and catalyze a dynamic data economy. In a previous post, we briefly described the essence of the envisioned heath data space and pointed at opportunities and… Read More »The Dawn of a European Health Data Space – Challenges
Prescient hires three new senior members to strengthen and grow its Intelligence & Insight business LONDON, July 15, 2020—Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members to its Intelligence & Insight business: Dr. Anuj Gupta, Rob… Read More »Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team